MAY 29, 2020 8:48 AM PDT

What can we do about drug-induced tetraploidy in cancer cells?

A paper published in the journal Trends in Cancer describes how cancer therapies sometimes fuel genetic changes in cells that lead to resistance. During this process, rogue cells grow in size, significantly expanding the number of chromosomes the cell should have. This phenomenon is of obvious concern to oncologists. Daruka Mahadevan, MD, PhD, has spent the last 20 years investigating this, and reports on a potential method for deterring it with co-author Gregory C. Rogers, Ph.D. Mahadevan is a professor and chief of the Division of Hematology-Oncology in the Long School of Medicine at UT Health San Antonio. 

"When you give therapy, some cells don't die," explained Dr. Mahadevan. "These cells don't die because they've acquired a double complement of the normal chromosomes plus other genetic changes. Many types of chemotherapy actually promote this."

Photo: Pixabay

The paper explains that these cells can have up to 8, 16, or even 32 times the number of chromosomes found in healthy cells. The authors say that two specific genes, c-Myc and BCL2, drive the genetic changes in the tetraploid cells. c-Myc and BCL2 are known to play a role in "double-hit" high-grade lymphomas, which are incurable.

"These genes are part of the problem because when they are present, they help the lymphoma cells to live longer and prime them to become large cells with treatment," said Mahadevan."It's a double hit, a double whammy."

These tetraploid cells will eventually result in cancer recurrence. As the authors write, “Drug-induced tetraploidy (DIT) in cancer cells is not only a mechanism of inherited drug resistance; proliferating DIT cells can produce progeny with increased ploidy or aneuploid genomes that drive aggressive disease.”

In response to this phenomenon, Mahadevan and Rogers have identified a small-molecule inhibitor that could prevent or treat DIT in cancer cells. The idea is that such a drug, once developed, could be used in concordance with chemotherapies to prevent large cell resistance.

Sources: Trends in Cancer, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 19, 2020
Drug Discovery & Development
APR 19, 2020
FDA Approves New Drug for Breast Cancer
The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced f ...
MAY 04, 2020
Cancer
MAY 04, 2020
A Retroactive Study Finds an Immunotherapy Effective as a Third-Line Therapy
Cancer is a particularly persistent disease. Many therapies are composed of one or more different treatments. These trea ...
MAY 11, 2020
Cancer
MAY 11, 2020
Using Deep Learning to Diagnose Breast Cancer Sub-Types
Cancer and computer programming may not sound like two things that go together. However, advanced programming techniques ...
JUN 05, 2020
Cancer
JUN 05, 2020
Diet can influence effectiveness of chemotherapy
Can changing your diet improve chemotherapy results? New research published in Nature Communications suggests that diet- ...
JUN 25, 2020
Cancer
JUN 25, 2020
Examining the Glioma Influenced Immune System
The human body is a complicated network of systems and signals.  Many systems regulate themselves or others in vari ...
JUN 23, 2020
Cancer
JUN 23, 2020
Why are certain people more vulnerable to carcinogens?
A study from the University of Hawaii Cancer Center entitled, "Tumour predisposition and cancer syndromes as models ...
Loading Comments...